Table 3 Drug response SNPs
From: Sequencing and analysis of a South Asian-Indian personal genome
# | Drug/Condition | Chromosomal location | Gene | Genotype | SNP-ID | Drug related outcome |
|---|---|---|---|---|---|---|
1 | Interferon beta therapy for multiple sclerosis (MS) | chr13:92884370 | GPC5 | CT | rs7987675 | will likely not show increase response to interferon beta therapy in case of relapsed MS |
2 | Lumiracoxib-related liver toxicity | chr6:32305978 | C6orf10 | GT | rs3129900 | increase in liver toxicity risk in response to lumiracoxib used to treat acute pain and osteoarthritic symptoms |
3 | Metformin Response | chr11:108239628 | ATM-C11orf65 | GG | rs4585 | will respond better to Metformin |
4 | Ribavirin-induced anemia | chr20:3193842 | ITPA | CA | rs1127354 | greatly decreased odds of developing anemia when taking PEG-IFN/RBV |
5 | Statin induced myopathy | chr12:21331549 | SLCO1B1 | TT | rs4149056 | typical dose of Simvastin will not increase myopathy risk |
6 | Floxacillin and liver toxicity | chr6:31431780 | HCP5 | TT | rs2395029 | at typical dose liver toxicity is not expected in response to floxacillin |
7 | Beta-Blocker - heart failure risk | chr10:115805056 | ADRB1 | CC | rs1801253 | Bucindolol is unlikely to reduce mortality odds in case of heart failure |
8 | Response to amitriptyline | chr7:87160561 | ABCB1 | AA | rs2032583 | typical response to depression when treated with Elavil, Paxil, Effexor, or Celexa |
9 | Warfarin sensitivity | chr10:96702047 | CYP2C9 | CC | rs1799853 | typical dose of warfarin does not increase risk of bleeding |
chr10:96741053 | CYP2C9 | AA | rs1057910 | |||
chr16:31107689 | VKORC1 | CC | rs9923231 | |||
promoter | ||||||
10 | Fluorouracil toxicity | chr1:97915613 | DPYD | CC | rs3918290 | No copies of the DPYD*2A mutation. May still be at risk for 5-FU toxicity due to other genetic or non-genetic factors |